Showing 126-130 of 254 resources:
Clinical and Economic Benefit of Achieving Disease Control in Psoriatic Arthritis and Ankylosing Spondylitis: A Retrospective Analysis from the OM1 Registry

Springer Link Publish Date: November 4, 2022 Read the Full Article >>   Abstract Background There is limited evidence on the clinical and economic benefit of achieving disease control in psoriatic arthritis (PsA) and ankylosing spondylitis (AS), thus we aimed to assess the impact of disease control on healthcare resource use (HCRU) and direct medical[…]

Many Female Arthritis Drug Users Face Restrictions After Dobbs

Bloomberg Law Publish Date: November 14, 2022 Read the Full Article >> More than half of women ages 15 to 49 who use a common arthritis drug risk losing access under restrictive state abortion laws, according to a new study based on nationwide health-care data. The analysis, published Saturday in the Arthritis & Rheumatology Journal, found[…]

Personalizing Medicine: AI and RWE in the Medtech Context

AdvaMed Publish Date: November 3, 2022 Read the Full Article>> Challenges of AI in MedTech In the medical device space, powerful insights from real-world data can seem ‘just out of reach’. Capturing patient characteristics and outcomes, at scale and with consistency over time, is challenging outside of clinical trials. Personalization – bridging the gap between[…]

Using Real-World Data to Understand Treatment Resistant Depression

Listen to OM1’s podcast episode on the Medical Affairs Professional Society (MAPS) “Elevate” podcast series. Dr. Carl Marci is discussing the use of Real-World Data and Real-World Evidence to understand and possibly intercede in treatment-resistant depression and why it is especially difficult to develop treatments against resistant depression using the traditional structure of R&D-led clinical[…]

Advancing Personalized Medicine for Health Plans: How AI and RWE can improve outcomes, reduce costs, and improve member engageme

Tue, Oct 18, 2022 11:00 AM – 12:00 PM EDT Presenter: Joseph Zabinski, Senior Director, AI & Precision Medicine, OM1 Register >> As population health moves towards personalized, precision medicine, optimizing treatment options and reducing ineffective care will be critical to plans’ success and differentiation in highly competitive environments. Real-world evidence drawn from deep datasets[…]

1 … 24 25 26 27 28 … 51